Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited (ZLAB) is a global biopharmaceutical innovator developing therapies for oncology, autoimmune disorders, and infectious diseases. This news hub provides verified updates on clinical advancements, regulatory milestones, and strategic partnerships critical to investors and healthcare professionals.
Access official press releases and curated news covering clinical trial results, regulatory submissions, collaboration announcements, and financial disclosures. Monitor ZLAB's progress in combining proprietary research with in-licensed therapies through a centralized, reliable source.
Stay informed about pipeline developments and global operations with factual reporting that emphasizes scientific rigor and regulatory expertise. This resource eliminates speculation while highlighting initiatives directly impacting patient care and market positioning.
Bookmark this page for efficient tracking of ZLAB's advancements. Return regularly for authoritative updates on therapeutic innovations addressing complex medical challenges worldwide.
Zai Lab Limited (NASDAQ: ZLAB) announced a strategic partnership with MediLink Therapeutics, acquiring an exclusive worldwide license for YL212, a novel DLL3 ADC aimed at treating lung cancer. This collaboration enhances Zai Lab's oncology pipeline and lung cancer franchise, as YL212 is developed using MediLink’s proprietary TAMLIN® platform. The DLL3 target is overexpressed in small cell lung cancer (SCLC), indicating significant potential for addressing unmet medical needs. Zai Lab will oversee global development and commercialization, with MediLink receiving milestone payments and royalties. The partnership reflects Zai Lab's strategic focus on innovative cancer therapies and complements its existing lung cancer portfolio, which includes the recently approved TIVDAK for cervical cancer.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that the results from the phase 3 LUNAR clinical trial in metastatic non-small cell lung cancer (NSCLC) will be presented at the upcoming ASCO Annual Meeting from June 2 to June 6, 2023. Conducted by their partner NovoCure Limited, the trial evaluates the combination of Tumor Treating Fields (TTFields) therapy with standard treatments after prior platinum-based therapy. Notably, the trial met its primary endpoint, showing a statistically significant improvement in overall survival when TTFields was combined with standard therapies. This presentation represents a significant advancement in addressing the unmet needs of lung cancer patients, especially in China, where around 700,000 new NSCLC cases are diagnosed annually. The presentation will occur on June 6 at 11:09 a.m. CDT, marking a pivotal moment for Zai Lab in the oncology landscape.
FAQ
What is the current stock price of Zai Lab (ZLAB)?
What is the market cap of Zai Lab (ZLAB)?
